Comparative Study of Sclerostin and Lipid Profile in Type 2 Diabetic Patients of Iraqi Women with Osteoporosis

Abeer Abaas Jafer a1, Bushra Hameed Ali2
Department of Chemistry, College of Education for Pure Science,
Ibn Al-Haitham – University of Baghdad, Baghdad, Iraq

* Corresponding Author: Abeer Abaas Jafer, Email: abeermastar@gmail.com, Mobile: +964 771 457 0528

ABSTRACT
Background: Chronic hyperglycemia is the most frequent diabetes-related metabolic disorder because of faulty insulin action or production. According to the WHO, osteoporosis is a progressive systemic skeletal disorder that decreases bone mass and micro architecture bone tissue, increasing bone fragility and fracture risk. Nervosa damage determines how much a diabetic's body is damaged.

Objective: The current work aimed to examines age, BMI, HbA1c, fasting blood glucose, sclerostin, and lipid profiles (TC, TG, HDL-C, VLDL-C, and LDL-C) in Iraqi T2DM menopausal women with /without osteoporosis to detect biomarkers in such condition.

Subjects and Methods: 120 subjects were included in this study. They were divided into 3 groups; Group 1 (N = 40) consisted of seemingly healthy women, group 2 (N = 40) included type 2 diabetes patients without osteoporosis and group 3 (N = 40) included type 2 diabetes patients with osteoporosis. The patients were recruited from the Endocrinology and Diabetes Center of the Iraqi Ministry of Health in Baghdad between January and June 2022. The ages of participants ranged from 45 to 55 years. Glucose, HbA1c, sclerostin, and lipid profiles were measured. The t-test, mean, standard division, and other bio statistical approaches were used to examine the data.

Results: Various data were observed in osteoporosis patients with and without T2DM in Iraqi postmenopausal women regarding Sclerostin and other anthropometric parameters and biomarkers studied. Conclusion: Type 2 diabetic Iraqi women with and without osteoporosis had significantly lower Sclerostin levels than controls. Sclerostin correlates with BMI, HbA1c, FBG, and lipid profile (TC, TG, HDL-C, VLDL-C and LDL-C).

Keywords: T2DM, Sclerostin, Osteoporosis, HDL-C, BMI.

INTRODUCTION
The term "chronic hyperglycemia" refers to the most prevalent metabolic disorder among people with diabetes mellitus. The culprit is either insulin synthesis, insulin action, or both of these mechanisms. Chronic hyperglycemia has been linked to ketoadidosis, nephropathy, high blood pressure, and foot issues. Numerous complementary and alternative therapies can be used to treat diabetes (1,2). Diabetes mellitus, or DM, is one of the most ancient illnesses to impact people and is a metabolic disorder characterized by an increase in blood glucose levels, calls for close monitoring and efficient therapy. In addition to helping cells absorb glucose for energy, the hormone insulin, which is produced by pancreatic beta cells, also has a number of additional functions. A decrease in insulin production or sensitivity causes diabetes mellitus (DM) (3).

According to the World Health Organization, osteoporosis is a slowly progressing systemic skeletal condition marked by a decline in bone mass and the microstructural breakdown of bone tissue, which raises the risk of fracture (WHO).

Fractures occurred less commonly in premenopausal women than in postmenopausal women. According to the World Health Organization, osteoporosis is detected in postmenopausal women when their hip or spine bone mineral density (BMD) is two and a half standard deviations or more below the young adult mean (T-score = 2.5). There are conflicting opinions on how to detect osteoporosis in premenopausal women (4). Osteoporosis is a condition where there is a loss of bone mass and mineral density, which makes bones more brittle and prone to fracture at modest forces. Fragility fractures occur when someone slides or falls, typically from a standing or seated posture. Hip, spine, and wrist fractures are the most common types of fragility fractures (5). The protein sclerostin, which is produced by the SOST gene, controls bone growth by inhibiting the Wnt/β-catenin signaling pathway. Genetic anomalies in the SOST gene can lead to sclerosteosis and Van Buchem disease. Both conditions differ in that blood sclerostin levels are undetectable or incredibly low, leading to considerable bone overgrowth (6). Sclerostin, an osteoclast-secreted glycoprotein of 190 amino acids, is a potent inhibitor of osteoblastogenesis. Osteocytes release sclerostin, which travels through osteocyte canaliculi to the surface of the bone. There, it binds to the LRP5 and LRP6 co-receptors, which hinder co-localization with the frizzled protein and Wnt signaling, hence inhibiting osteoblastogenesis and bone formation (7).

MATERIALS AND METHODS
The current study was conducted in the Endocrinology and Diabetes Center, Iraqi Ministry of Health, Baghdad. Three groups the first group (G1) consisted of 40 individual made up of participants in this study, each with an age range of 45 to 55 years.

The 40 people in the second group are type 2 diabetic patients without osteoporosis, and the third group comprised forty individuals with type 2 diabetes and osteoporosis.
Ethical approval:
The research approved by Endocrinology and Diabetes Center, Iraqi Ministry of Health’s Ethics Committee and the College of Education for Pure Science / Ibn Al-Haitham – University of Baghdad. A consent document was signed by all those involved. The World Medical Association's Declaration of Helsinki was strictly adhered to in all human subjects' studies.

Statistical analysis
The data were computed using the Student T-test, mean ± SD, and other findings were provided. The extraction P-value and post t-test were both utilized to show the difference between the groups with significance when the P ≤ 0.05 in the test that compared the three study groups.

RESULT
In order to analyze the link between the three groups, 120 study participants were split into three groups: apparently healthy as controls (G1), people with type 2 diabetes mellitus (G2) without osteoporosis, and type 2 diabetic patients with osteoporosis (G3).

Table (1) described the correlation and the result of the comparison obtained.

BMI that was shown in the same table and figure (1) indicated a highly significant decrease in G1 (25.74 ± 3.35 kg/m²) to G2 (30.26 ± 2.89 kg/m²) and G3 (28.50 ± 3.39 kg/m²), but also significant increase (P<0.005) as compared between G2 (30.26 ± 2.89 kg/m²) to G3 (28.50 ± 3.39 kg/m²). Regarding fasting blood glucose, table (1) and figure (2) showed a high significant value (P<0.001), when comparing between G1 (82.65 ± 5.77 mg/dl) and G2 (204.75 ± 56.72 mg/dl) and G3 (159.3 ± 28.86 mg/dl).

Also, a high significant (P<0.001) with increased level in G2 (204.75 ± 56.72 mg/dl) as compared to G3 (159.3 ± 28.86 mg/dl).

Table (1): Various markers obtained in postmenopausal T2DM women with/without osteoporosis

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Apparently Healthy Control Group (G1) N = 40</th>
<th>T2DM Group (G2) N = 40</th>
<th>T2DM with Osteoporosis Group (G3) N = 40</th>
<th>G1 Vs. G2</th>
<th>G1 Vs. G3</th>
<th>G2 Vs. G3</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m²</td>
<td>25.74 ± 3.35</td>
<td>30.26 ± 2.89</td>
<td>28.50 ± 3.50</td>
<td>HS</td>
<td>HS</td>
<td>S</td>
</tr>
<tr>
<td>FBG, mg/dl</td>
<td>82.65 ± 5.77</td>
<td>204.75 ± 6.72</td>
<td>159.3 ± 28.86</td>
<td>HS</td>
<td>HS</td>
<td>HS</td>
</tr>
<tr>
<td>HbA1c%</td>
<td>4.74 ± 0.43</td>
<td>8.64 ± 1.42</td>
<td>8.64 ± 1.39</td>
<td>HS</td>
<td>HS</td>
<td>NS</td>
</tr>
<tr>
<td>Sclerostin</td>
<td>741.97 ± 128.21</td>
<td>616.45 ± 81.76</td>
<td>471.55 ± 142.02</td>
<td>HS</td>
<td>HS</td>
<td>HS</td>
</tr>
<tr>
<td>TC, mg/dl</td>
<td>157.35 ± 23.22</td>
<td>230.25 ± 49.52</td>
<td>237.75 ± 55.69</td>
<td>HS</td>
<td>HS</td>
<td>NS</td>
</tr>
<tr>
<td>TG, mg/dl</td>
<td>130.27 ± 11.54</td>
<td>267.82 ± 58.50</td>
<td>203.92 ± 60.25</td>
<td>HS</td>
<td>HS</td>
<td>HS</td>
</tr>
<tr>
<td>HDL-C, mg/dl</td>
<td>50.74 ± 4.83</td>
<td>34.65 ± 1.29</td>
<td>38.85 ± 4.74</td>
<td>HS</td>
<td>HS</td>
<td>HS</td>
</tr>
<tr>
<td>LDL-C, mg/dl</td>
<td>124.64 ± 27.54</td>
<td>249.19 ± 50.18</td>
<td>237.30 ± 56.42</td>
<td>HS</td>
<td>HS</td>
<td>NS</td>
</tr>
<tr>
<td>VLDL-C, mg/dl</td>
<td>20.65 ± 2.30</td>
<td>53.65 ± 11.70</td>
<td>40.60 ± 12.22</td>
<td>HS</td>
<td>HS</td>
<td>HS</td>
</tr>
</tbody>
</table>
Concerning HbA1c\%, table (1) and figure (3) indicated a high significant decreased value (P˂0.001) when comparing G1 (4.74 ± 0.43) with G2 (8.64 ± 1.42) and G3 (8.64 ± 1.39), but a non-significant result (P˃0.005) when comparing G2 (8.64 ± 1.42) and G3 (8.64 ± 1.39).

Regarding sclerostin, table (1) and figure (4) showed a high significant increase (P<0.001) when comparing G1 (741.97 ± 128.21) with G2 (616.54 ± 81.76) and G3 (471.55 ± 142.02), and a high significant increase (P<0.001) as compared G2 (616.54 ± 81.76) to G3 (471.55 ± 142.02).

About TG, table (1) and figure (6) indicated a high significant decreased (P<0.001) in G1 (103.27 ± 11.54 mg/dl) as compared to G2 (267.82 ± 58.50 mg/dl) and G3 (203.92 ± 60.25 mg/dl). While there was a significant increase in G2 (267.82 ± 58.50 mg/dl) as compared to G3 (203.92 ± 60.25 mg/dl).
Regarding HDL-C, table (1) and figure (7) indicated a high significant increased levels (P<0.001) in G1 (50.75 ± 4.83 mg/dl) as compared to G2 (34.65 ± 1.29 mg/dl) and G3 (38.85 ± 4.47 mg/dl). While, there was a significant decrease in G2 (34.65 ± 1.29 mg/dl) as compared to G3 (38.85 ± 4.47 mg/dl) (P < 0.001).

Concerning LDL-C, table (1) and figure (8) indicated a high significant decreased level in G1 (124.64 ± 27.54 mg/dl) as compared to G2 (249.19 ± 50.18 mg/dl) and G3 (237.30 ± 56.42 mg/dl). While, there was significant increase in G2 (P < 0.05) when compared to G3 (237.3 ± 50.18 mg/dl) and G1 (124.64 ± 27.54 mg/dl).

As regards VLDL-C, table (1) and figure (9) indicated a high significant decreased value (P<0.001) in G1 (20.65 ± 2.30 mg/dl) when compared to G2 (53.65 ± 11.70 mg/dl) and G3 (40.60 ± 12.22 mg/dl). While, there was a high significant increase in G2 when compared G1 (20.65 ± 2.30 mg/dl) and G3 (40.60 ± 12.22 mg/dl).

Table (2) showed the correlations between sclerostin with levels of BMI for G2 and G3 respectively where there were highly significant negative correlation (P ≤0.001) with G2 (r = -0.0102) and G3 (r = -0.069), while the correlations between sclerostin and FBG levels for G2 and G3 showed highly significant positive correlation (P ≤0.001) with G2 (r = 0.1546) and G3 (r = 0.097) respectively.

The other correlations studied between sclerostin and HbA1c% indicated a highly significant negative and positive correlation (P ≤0.00) for G2 (r = -0.2122) and G3 (r = 0.104) respectively. On the other hand, the correlations with TC showed highly significant negative and positive results (P ≤0.001) for G2 (r = -0.0175) and G3 (r = 0.0733) respectively, while the correlation with TG showed a highly significant positive correlation (P ≤0.001) for each of G2 (r = 0.1220) and G3 (r = 0.407).

The other correlations study performed between sclerostin with each of HDL-C and LDL-C; HDL-C showed highly significant negative and positive correlations (P ≤0.001) for G2 (r = -0.2424) and G3 (r = 0.332), while LDL-C showed highly significant positive and negative correlation (P ≤0.001) for G2 (r = 0.0517) and G3 (r = -0.015) respectively.

The correlations between sclerostin and the biomarker VLDL-C indicated a highly significant positive and negative correlations (P ≤0.001) for G2 (r = 0.1220) and G3 (r = -0.407) respectively.
Women were investigated for increased Sclerostin in T2DM. The slight increase in sclerostin levels may be associated with a lower risk of fracture in women and T2DM women with osteoporosis. Our study showed that patient BMI values were significantly higher than those of the control group. This evidence is in line with other research that observed a connection between a higher BMI and high levels of insulin resistance, which in turn resulted in a reduction in insulin sensitivity to lower glucose levels in older persons. Also, a recent study observed that BMI in osteoporosis women postmenopausal was significantly high as compared to healthy women. An abrupt decline in bone mineral density and an uptick in inflammatory markers are indicators of rapid bone loss in postmenopausal osteoporotic women. In terms of BMI, there was no discernible difference between patients and controls, which is similar to the current results. Other investigators indicated that FBG was significantly elevated among T2DM patients and postmenopausal women and is an indicative of osteoporosis.

Aberrant glucose metabolism (AGM) in osteoporosis is usually identified using fasting glucose, which encompasses the normal, impaired fasting glucose (IFG), and diabetes mellitus (DM) guideline fasting glucose categories. Examining the relationship between the risk of osteoporosis and fasting glucose level may be useful in understanding how AGM influences the condition. However, nothing is known about how fasting glucose and osteoporosis are related. It is common practice to diagnose AGM, which includes IFG, impaired glucose tolerance (IGT), and DM, using fasting glucose and two hours following a load of glucose. Despite earlier research relating AGM and bone quality, the evidence currently available is insufficient to establish the impact of IFG on osteoporosis. Our study showed that IFG prevented osteoporosis and strengthened bones.

Table (2): The correlations between Sclerostin with various parameters studied: (BMI, FBG, HbA1c, TC, TG, HDL-C, LDL-C and VLDL-C)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>G2 T2DM</th>
<th></th>
<th>G3 T2DM with Osteoporosis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r</td>
<td>p-value</td>
<td>r</td>
<td>p-value</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>-0.0102</td>
<td>HS</td>
<td>-0.069</td>
<td>HS</td>
</tr>
<tr>
<td>FBG, mg/dl</td>
<td>0.1546</td>
<td>HS</td>
<td>0.097</td>
<td>HS</td>
</tr>
<tr>
<td>HbA1c%</td>
<td>-0.2122</td>
<td>HS</td>
<td>0.104</td>
<td>HS</td>
</tr>
<tr>
<td>TC, mg/dl</td>
<td>-0.0175</td>
<td>HS</td>
<td>0.0733</td>
<td>HS</td>
</tr>
<tr>
<td>TG, mg/dl</td>
<td>0.1220</td>
<td>HS</td>
<td>0.407</td>
<td>HS</td>
</tr>
<tr>
<td>LDL-C, mg/dl</td>
<td>-0.2424</td>
<td>HS</td>
<td>0.332</td>
<td>HS</td>
</tr>
<tr>
<td>VLDL-C, mg/dl</td>
<td>0.0517</td>
<td>HS</td>
<td>-0.015</td>
<td>HS</td>
</tr>
<tr>
<td>HDL-C, mg/dl</td>
<td>0.1220</td>
<td>HS</td>
<td>-0.407</td>
<td>HS</td>
</tr>
</tbody>
</table>

DISCUSSION

Various studies regarding osteoporosis studies in postmenopausal women were investigated with and without another diseases such as T2DM. According to results obtained from the current study we noticed a highly significant decreased sclerostin levels for Iraqi women’s with type 2 diabetes mellitus with and without osteoporosis when compared with control group, this may be due to aging and menopausal cycle. These variables led to abnormality in osteoblast and osteoclast as well as when progressed in diabetic due to osteoporosis and led to more decrease in sclerostin concentration. While, another study noticed a highly levels of sclerostin may be related with postmenopausal women and T2DM. Sclerostin levels and the risk of fracture may or may not be related. Higher sclerostin levels may be associated with a lower risk of fracture because of the strong relationship between sclerostin levels and bone mineral density (BMD). In another way, mature bone tissue with firmly implanted osteocytes produce sclerostin rather than early embedding osteoid osteocytes and juvenile osteocytes. In line with the previous studies, sclerostin was decreased significantly in women with osteoporosis post-menopause. The Wnt pathway signaling, which regulates bone formation, is inhibited by sclerostin. Low levels of the circulating sclerostin protein lead to high bone mass. The researchers hypothesized that postmenopausal women with high sclerostin levels would be more susceptible to fractures caused by osteoporosis. Previous studies performed by Marzullo et al. showed that sclerostin was increased significantly in T2DM women postmenopausal with osteoporosis and hormones that control bone growth. In order to identify potential bone status modulators in obesity, we looked into the role of sclerostin and the premenopausal hormone status that controls it as a mechanism that promotes bone resorption. The studies have shown that sclerostin levels increase with aging, menopause, insulin resistance, and T2DM. The slight increase in sclerostin levels in postmenopausal women supports earlier findings that sclerostin levels grow gradually after menopause.

When it comes to sex steroids, testosterone has been found in both experimental and clinical trials to have the opposite impact of estrogen, which is known to increase circulation and bone sclerostin mRNA levels. In another study carried by Zhao et al., which investigated that patient BMI values were significantly higher than those of the control group. This evidence is in line with other research that observed a connection between a higher BMI and high levels of insulin resistance, which in turn resulted in a reduction in insulin sensitivity to lower glucose levels in older persons. Also, a recent study observed that BMI in osteoporosis women postmenopausal was significantly high as compared to healthy women. An abrupt decline in bone mineral density and an uptick in inflammatory markers are indicators of rapid bone loss in postmenopausal osteoporotic women. In terms of BMI, there was no discernible difference between patients and controls, which is similar to the current results. Other investigators indicated that FBG was significantly elevated among T2DM patients and postmenopausal women and is an indicative of osteoporosis.

Aberrant glucose metabolism (AGM) in osteoporosis is usually identified using fasting glucose, which encompasses the normal, impaired fasting glucose (IFG), and diabetes mellitus (DM) guideline fasting glucose categories. Examining the relationship between the risk of osteoporosis and fasting glucose level may be useful in understanding how AGM influences the condition. However, nothing is known about how fasting glucose and osteoporosis are related. It is common practice to diagnose AGM, which includes IFG, impaired glucose tolerance (IGT), and DM, using fasting glucose and two hours following a load of glucose. Despite earlier research relating AGM and bone quality, the evidence currently available is insufficient to establish the impact of IFG on osteoporosis. Our study showed that IFG prevented osteoporosis and strengthened bones.
These findings are almost conclusive with others which observed that HbA1c was non-significantly between T2DM without osteoporosis and T2DM with osteoporosis. Higher blood glucose or HbA1c levels have been linked in a number of ways with an increased risk of reduced muscle mass, according to earlier studies. Insulin resistance and AGEs are the two main risk factors. Insulin resistance is a hallmark of T2DM, and it is linked to a number of inflammatory markers, such as IL-6, tumor necrosis factor alpha, and C-reactive protein (CRP). The synthesis and degradation of muscle proteins are both a part of muscle protein metabolism. The four primary proteolytic mechanisms that break down muscle protein are regulated by inflammatory signaling: Calpains, macrophage autophagy, and cell death are all ATP dependent ubiquitin proteasome activities (16).

In another study performed by Kan et al. (17) indicated that total cholesterol was highly significant in osteoporosis women and type 2 diabetes mellitus. The majority of the postmenopausal women in our study (82.5%) had T2DM as a chronic condition. These conditions were assumed to be related to lipids and osteoporosis. Numerous biological pathways can be used to account for the positive relationships between TC levels and BMD. However, the majority of studies investigating the link between lipids and osteoporosis relied on people who were typically in good condition. First, the researchers hypothesize that the nuclear hormone receptor peroxisome proliferator activated receptor γ (PPAR γ) may play a part in the relationship between lipid biomarkers and BMD. The PPAR γ gene can be activated by lipid metabolites. When PPAR γ levels increase, osteogenesis is inhibited, which causes more bone loss. Second, larger amounts of lipids are associated with more oxidized lipids and oxidative stress. The development of osteoblasts and adipocytes may be hampered or promoted by higher levels of oxidative stress.

This observation is in line with a lot of academic works by Yamaguchi et al. (18) in which triglycerides was non-signification between control women postmenopausal and osteoporosis. Malnutrition has the potential to induce or aggravate a wide range of disorders, including osteoporosis. Triglycerides were included as a potential variable in this study because blood lipid levels, particularly triglycerides, may be an indicator of nutritional status. Additionally, past studies on the connection between triglycerides and osteoporosis were contradictory. In a study with 214 postmenopausal women in Japan, lower TG was connected to a higher risk of vertebral fractures. However, a Korean analysis found no connection between serum lipid levels and BMD in postmenopausal women. Another study by Tang et al. (19) reported non-significantly in osteoporosis and control women to those of another study, which discovered that women with high HDL-C levels had a higher incidence of osteopenia or osteoporosis, suggesting that HDL-C levels may be a good indicator of osteopenia or osteoporosis. Through sex hormones, HDL-C, especially at high levels, affects BMD. Numerous studies have already established the significance of sex hormones like androgen and estrogen in preserving bone homeostasis.

Other result obtained by Cui et al. (20) indicated that serum levels of HDL-C levels was non-significantly in osteoporosis Iranian women's and found to be inversely correlated with BMD in postmenopausal women with inadequate vitamin D3 levels. Other studies related serum LDL-C levels indicated a significant result in osteoporosis postmenopausal women, which may be a significant factor, independent of bone markers, BMD, frailty, or use of medications for dyslipidemia. High serum LDL-C levels are equally detrimental to bone and blood vessels as type 2 diabetes and chronic renal illness, despite the fact that they are known to be a risk factor for atherosclerosis and cardiovascular events. Our results and others investigated an inverse relationship between serum LDL-C levels and both radial and overall BMD. In their study that involved 355 Korean postmenopausal women, LDL-C was significantly lower in the highest quartile of blood LDL-C levels than in the lowest quartile.

Women with T2DM have increased capacity for producing and secreting very low density lipoprotein (VLDL) in fatty tissue than women without this type 2 diabetes, suggesting that metabolic problems are caused by VLDL (21). Other investigators indicated that VLDL has been increased significantly in postmenopausal women with osteoporosis as compared to healthy control. The VLDL was connected to vascular calcifications and bone loss in diabetic women. This demonstrates that the association between vascular calcifications and bone loss may be reflected in VLDL levels. Osteoporosis patients may have faster lipid metabolism than healthy controls, which could account for the low levels of VLDL particles. This could be connected to statins’ impact on lipoprotein metabolism (22). Also, other studies indicated that VLDL-C is significantly increased in women with osteoporosis when compared to without osteoporosis (23). Most of diseases may correlated with genetic reasons, for that, The molecular technique (PCR) was recommended to applied in different medical field like diagnosis genetic disease ex: CML (24), Adenocarcinoma (25,26), and SARS-Cov-2 (27).

**CONCLUSION**

According to results obtained from the present study we noticed highly significant decrease in concentration of sclerosistin for Iraqi type 2 diabetic women's with and without osteoporosis when compared to control as well as we showed highly significant correlation when compared between sclerosistin and BMI, HbA1c, FBG, lipid profile (TC, TG, HDL-C, VLDL-C and LDL-C). These changes could promote
REFERENCES


